These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31520497)

  • 21. Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia.
    Chambers MS; Jones CU; Biel MA; Weber RS; Hodge KM; Chen Y; Holland JM; Ship JA; Vitti R; Armstrong I; Garden AS; Haddad R
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1369-76. PubMed ID: 17855005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cevimeline on radiation-induced salivary gland dysfunction and AQP5 in submandibular gland in mice.
    Takakura K; Takaki S; Takeda I; Hanaue N; Kizu Y; Tonogi M; Yamane GY
    Bull Tokyo Dent Coll; 2007 May; 48(2):47-56. PubMed ID: 17978545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.
    Brimhall J; Jhaveri MA; Yepes JF
    Spec Care Dentist; 2013; 33(3):123-7. PubMed ID: 23600983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.
    Ono M; Takamura E; Shinozaki K; Tsumura T; Hamano T; Yagi Y; Tsubota K
    Am J Ophthalmol; 2004 Jul; 138(1):6-17. PubMed ID: 15234277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth).
    Malallah OS; Garcia CMA; Proctor GB; Forbes B; Royall PG
    Int J Pharm; 2018 Apr; 541(1-2):157-166. PubMed ID: 29425763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren's syndrome.
    Garlapati K; Kammari A; Badam RK; B E S; Boringi M; Soni P
    Immunopharmacol Immunotoxicol; 2019 Apr; 41(2):312-318. PubMed ID: 30932714
    [No Abstract]   [Full Text] [Related]  

  • 27. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.
    Witsell DL; Stinnett S; Chambers MS
    Head Neck; 2012 Aug; 34(8):1136-42. PubMed ID: 22231734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of oral pilocarpine in xerostomia and Sjögren's syndrome.
    Nusair S; Rubinow A
    Semin Arthritis Rheum; 1999 Jun; 28(6):360-7. PubMed ID: 10406404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salivary hypofunction and xerostomia: diagnosis and treatment.
    Atkinson JC; Grisius M; Massey W
    Dent Clin North Am; 2005 Apr; 49(2):309-26. PubMed ID: 15755407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy prediction of cevimeline in patients with Sjögren's syndrome.
    Yamada H; Nakagawa Y; Wakamatsu E; Sumida T; Yamachika S; Nomura Y; Mishima K; Saito I
    Clin Rheumatol; 2007 Aug; 26(8):1320-7. PubMed ID: 17221146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome.
    Rhodus NL
    Oral Dis; 1997 Jun; 3(2):93-8. PubMed ID: 9467349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.
    Nieuw Amerongen AV; Veerman EC
    Support Care Cancer; 2003 Apr; 11(4):226-31. PubMed ID: 12673460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effectiveness of cevimeline hydrochloride on dry cough in Sjögren's syndrome].
    Nishinarita M; Hanzawa M; Iikuni N; Ota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Apr; 27(2):99-102. PubMed ID: 15164930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Artificial saliva products and drugs to treat xerostomia.
    Wynn RL; Meiller TF
    Gen Dent; 2000; 48(6):630-6. PubMed ID: 12004654
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of 0.1% pilocarpine mouthwash on xerostomia: double-blind, randomised controlled trial.
    Kim JH; Ahn HJ; Choi JH; Jung DW; Kwon JS
    J Oral Rehabil; 2014 Mar; 41(3):226-35. PubMed ID: 24527846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09.
    Fisher J; Scott C; Scarantino CW; Leveque FG; White RL; Rotman M; Hodson DI; Meredith RF; Foote R; Bachman DG; Lee N
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):832-6. PubMed ID: 12788192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats.
    Ono K; Inagaki T; Iida T; Wakasugi-Sato N; Hosokawa R; Inenaga K
    Arch Oral Biol; 2012 Apr; 57(4):421-8. PubMed ID: 22099058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia.
    Jha N; Seikaly H; Harris J; Williams D; Sultanem K; Hier M; Ghosh S; Black M; Butler J; Sutherland D; Kerr P; Barnaby P
    Head Neck; 2009 Feb; 31(2):234-43. PubMed ID: 19107948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interventions for dry mouth and hyposalivation in Sjögren's syndrome: A systematic review and meta-analysis.
    Al Hamad A; Lodi G; Porter S; Fedele S; Mercadante V
    Oral Dis; 2019 May; 25(4):1027-1047. PubMed ID: 30086205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of long-term pilocarpine due to increased muscarinic acetylcholine receptor 3 in salivary glands.
    Minagi HO; Ikai K; Araie T; Sakai M; Sakai T
    Biochem Biophys Res Commun; 2018 Sep; 503(2):1098-1102. PubMed ID: 29953856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.